Journal of the Korean Association of Oral and Maxillofacial Surgeons

The Korean Association of Oral and Maxillofacial Surgeons (대한구강악안면외과학회)
권호 표지

ANTICANCER EFFECT OF CKD-602(BELOTECAN, CAMTOBELL$^{(R)}$) ON THE ORAL CANCER CELL LINES

구강암 세포주에 대한 CKD-602의 항암 효과

  • Yun, Pil-Young (Department of Oral and Maxillofacial Surgery, College of Dentistry, Seoul National University) ;
  • Ok, Yong-Ju (Department of Oral and Maxillofacial Surgery, College of Dentistry, Seoul National University) ;
  • Myoung, Hoon (Department of Oral and Maxillofacial Surgery, College of Dentistry, Seoul National University) ;
  • Lee, Jong-Ho (Department of Oral and Maxillofacial Surgery, College of Dentistry, Seoul National University) ;
  • Kim, Myung-Jin (Department of Oral and Maxillofacial Surgery, College of Dentistry, Seoul National University)
  • 윤필영 (서울대학교 치과대학 구강악안면외과학교실) ;
  • 옥용주 (서울대학교 치과대학 구강악안면외과학교실) ;
  • 명훈 (서울대학교 치과대학 구강악안면외과학교실) ;
  • 이종호 (서울대학교 치과대학 구강악안면외과학교실) ;
  • 김명진 (서울대학교 치과대학 구강악안면외과학교실)
  • Published : 2005.02.28
Download PDF
⟨ Previous Next ⟩

Abstract

Purpose: CKD-602, a newly developed water-soluble campthotecin analogue, is a anticancer agent which act as a DNA topoisomerase I inhibitor. CKD-602 is known as more potent and tolerable agent. The main purposes of this study were to measure the cytotoxic effect of CKD-602 on the oral cancer cell lines and to evaluate the apoptotic aspect of dead cells. Materials and Methods: To determine the cytotoxic effect of CKD-602 on the oral cancer cell lines in comparison with various cell lines, such as lung cancer and colon cancer cell lines, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide(MTT) assay was performed. And apoptosis was analyzed using fluorescence-activated cell sorting(FACS) system. Results: CKD-602 decreased the viability of malignant cells in a dose dependent manner and in a time dependent manner. CKD-602 showed excellent cytotoxicity to the oral cancer cell lines. Also, apoptotic portion was increased in a dose dependent manner. Conclusion: These findings indicated that CKD-602 induced apoptotic cell death in the various cell lines including oral cancer cell lines. From the results, it was suggested that CKD-602 would be a potential therapeutic agent for the oral cancer. More successive researches on the anticancer effect of CKD-602 should be performed.

Keywords

References

  1. Hsiang YH, Liu LF: Identification of mammalian DNA topoisomerase I as an intracellular target of the anticancer drug camptothecin. Cancer Res 1988;48:1722-1726
  2. Wang Z, Droge P: Differential control of transcription-induced and overall DNA supercoiling by eukaryotic topoisomerases in vitro. EMBO J 1996;15:581-589
  3. Husain I, Mohler JL, Seigler HF, Besterman JM: Elevation of topoisomerase I messenger RNA, protein, and catalytic activity in human tumors: demonstration of tumor-type specificity and implications for cancer chemotherapy. Cancer Res 1994;54:539-546
  4. Takimoto CH, Wright J, Arbuck SG: Clinical applications of the camptothecins. Biochim Biophys Acta 1998;1400:107-119 https://doi.org/10.1016/S0167-4781(98)00130-4
  5. Rubin EH: DNA topoisomerase expression in tumors-a novel target for chemotherapy. Hum Pathol 2000;31:631-632 https://doi.org/10.1053/hupa.2000.8629
  6. Madden KR, Champoux JJ: Overexpression of human topoisomerase I in baby hamster kidney cells: hypersensitivity of clonal isolates to camptothecin. Cancer Res 1992;52:525-532
  7. Holden JA, Rahn MP, Jolles CJ, Vorobyev SV, Bronstein IB: Immunohistochemical detection of DNA topoisomerase I in formalin fixed, paraffin wax embedded normal tissues and in ovarian carcinomas. Mol Pathol 1997;50:247-253 https://doi.org/10.1136/mp.50.5.247
  8. Giovanella BC, Stehlin JS, Wall ME, Wani MC, Nicholas AW, Liu LF et al: DNA topoisomerase I-targeted chemotherapy of human colon cancer in xenografts. Science 1989;246:1046-1048 https://doi.org/10.1126/science.2555920
  9. Lee JH, Lee JM, Kim JK, Ahn SK, Lee SJ, Kim MY et al: Antitumor activity of 7-[2-(N-isopropylamino)ethyl]-(20S)-camptothecin, CKD602, as a potent DNA topoisomerase I inhibitor. Arch Pharm Res 1998;21:581-590 https://doi.org/10.1007/BF02975379
  10. Kim EJ, Lee RK, Suh JE, Han SS, Kim JK: Safety pharmacology of CKD-602, a novel anticancer agent. Arzneimittelforschung 2003; 53:272-279
  11. Evan G: Cancer-a matter of life and cell death. Int J Cancer 1997; 71:709-711 https://doi.org/10.1002/(SICI)1097-0215(19970529)71:5<709::AID-IJC2>3.0.CO;2-V
  12. Steller H: Mechanisms and genes of cellular suicide. Science 1995; 267:1445-1449 https://doi.org/10.1126/science.7878463
  13. Nagata S: Apoptosis by death factor. Cell 1997;88:355-365 https://doi.org/10.1016/S0092-8674(00)81874-7
  14. Thompson CB: Apoptosis in the pathogenesis and treatment of disease. Science 1995;267:1456-1462 https://doi.org/10.1126/science.7878464
  15. Clarke PG, Clarke S: Historic apoptosis. Nature 1995;378:230
  16. Kang MR, Muller MT, Chung IK: Telomeric DNA damage by topoisomerase I. A possible mechanism for cell killing by camptothecin. J Biol Chem 2004;279:12535-12541 https://doi.org/10.1074/jbc.M309779200